Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease

Exclusion Criteria

• •Subjects with known or suspected hypersensitivity, intolerance or allergy to any of the ingredients in eltrombopag tablets.
• •Evidence of portal vein thrombosis on abdominal imaging (ultrasound with Doppler or appropriate magnetic resonance imaging/computed tomography (MRI/CT) imaging techniques) within 3 months before the start of the study.
• •History of arterial or venous thrombosis (including Budd-Chiari Syndrome),
• •AND ≥ two of the following risk factors:
• •hereditary thrombophilic disorders (e.g. antithrombinIII (ATIII) deficiency, etc.)
• •hormone replacement therapy
• •systemic contraception therapy (containing oestrogen)
• •smoking
• •diabetes
• •hypercholesterolemia
• •medication for hypertension or cancer
• •Human Immunodeficiency Virus (HIV) infection.
• •History of drug/alcohol abuse or dependence within 1 year prior to screening.
• •Any disease condition associated with current active World Health Organization (WHO) Grade 3 or 4 bleeding.
• •Active infection requiring systemic antibiotic therapy.
• •Pregnant, nursing mothers, women who may be pregnant, or women who plan to become pregnant during the time of study participation.
• •Treatment with platelet transfusion within 2 weeks prior to Day 1.
• •Treatment with interferon within 4 weeks prior to Day 1.
• •Treatment with an investigational drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication.
• •History of platelet agglutination abnormality.
• •History of porphyria.
• •Subjects who are deemed unsuitable for the study by the investigator (or subinvestigator).